66 related articles for article (PubMed ID: 8252602)
1. Combined effect of the 5-HT2 receptor antagonist DV-7028 and aspirin or heparin on coronary cyclic flow reductions in dogs.
Tanaka T; Morishima Y; Watanabe K; Shibutani T; Yasuoka M; Shibano T
Cardiovasc Res; 1993 Jul; 27(7):1374-9. PubMed ID: 8252602
[TBL] [Abstract][Full Text] [Related]
2. The effects of alpha 2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries.
Bush LR; Campbell WB; Kern K; Tilton GD; Apprill P; Ashton J; Schmitz J; Buja LM; Willerson JT
Circ Res; 1984 Nov; 55(5):642-52. PubMed ID: 6488486
[TBL] [Abstract][Full Text] [Related]
3. Prevention by DV-7028, a selective 5-HT2 receptor antagonist, of the formation of coronary thrombi in dogs.
Morishima Y; Tanaka T; Watanabe K; Igarashi T; Yasuoka M; Shibano T
Cardiovasc Res; 1991 Sep; 25(9):727-30. PubMed ID: 1799906
[TBL] [Abstract][Full Text] [Related]
4. Inhibition by nitroglycerin of canine platelet aggregation and cyclic flow reductions in stenosed coronary arteries.
Tanaka T; Morishima Y; Watanabe K; Takahashi M; Shibano T
Methods Find Exp Clin Pharmacol; 1995 Dec; 17(10):693-700. PubMed ID: 9053590
[TBL] [Abstract][Full Text] [Related]
5. Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs.
Hsieh CP; Sakai K; Bruns GC; Dage RC
J Cardiovasc Pharmacol; 1994 Nov; 24(5):761-72. PubMed ID: 7532754
[TBL] [Abstract][Full Text] [Related]
6. Vascular and cardiac effects of DV-7028, a selective, 5-HT2-receptor antagonist in rats.
Pawlak D; Adamkiewicz M; Malyszko J; Takada A; Mysliwiec M; Buczko W
J Cardiovasc Pharmacol; 1998 Aug; 32(2):266-73. PubMed ID: 9700989
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibitory effects of aspirin and ethanol on adrenaline exacerbation of acute platelet thrombus formation in stenosed canine coronary arteries.
Keller JW; Folts JD
Cardiovasc Res; 1990 Mar; 24(3):191-7. PubMed ID: 2346953
[TBL] [Abstract][Full Text] [Related]
8. Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
Lewis GD; Witzke C; Colon-Hernandez P; Guerrero JL; Bloch KD; Semigran MJ
J Am Coll Cardiol; 2006 Apr; 47(7):1471-7. PubMed ID: 16580539
[TBL] [Abstract][Full Text] [Related]
9. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation?
Folts JD; Gallagher K; Rowe GG
Circulation; 1982 Feb; 65(2):248-55. PubMed ID: 7053882
[TBL] [Abstract][Full Text] [Related]
10. Serotonin S2 and thromboxane A2-prostaglandin H2 receptor blockade provide protection against epinephrine-induced cyclic flow variations in severely narrowed canine coronary arteries.
Ashton JH; Golino P; McNatt JM; Buja LM; Willerson JT
J Am Coll Cardiol; 1989 Mar; 13(3):755-63. PubMed ID: 2521875
[TBL] [Abstract][Full Text] [Related]
11. Effect of DV-7028, a novel serotonin 5-HT2 receptor antagonist on the cardiovascular system in rats.
Pawlak D; Małyszko J; Myśliwiec M; Takada A; Buczko W
Acta Physiol Hung; 1996; 84(3):325-6. PubMed ID: 9219625
[TBL] [Abstract][Full Text] [Related]
12. Platelet aggregation in partially obstructed vessels and its elimination with aspirin.
Folts JD; Crowell EB; Rowe GG
Circulation; 1976 Sep; 54(3):365-70. PubMed ID: 947567
[TBL] [Abstract][Full Text] [Related]
13. Combination of aspirin and metoclopramide produces a synergistic antithrombotic effect in a canine model of coronary artery thrombosis.
Duval N; Grosset A; O'Connor SE
Fundam Clin Pharmacol; 1997; 11(1):57-62. PubMed ID: 9182077
[TBL] [Abstract][Full Text] [Related]
14. Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries.
Folts JD; Rowe GG
Thromb Res; 1988 May; 50(4):507-16. PubMed ID: 3413717
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of a new 5-hydroxytryptamine2 receptor antagonist, DV-7028.
Shibano T; Tanaka T; Morishima Y; Yasuoka M; Watanabe K; Fujii F
Arch Int Pharmacodyn Ther; 1992; 319():114-28. PubMed ID: 1285670
[TBL] [Abstract][Full Text] [Related]
16. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog.
Roux SP; Tschopp TB; Kuhn H; Steiner B; Hadváry P
J Pharmacol Exp Ther; 1993 Jan; 264(1):501-8. PubMed ID: 8423548
[TBL] [Abstract][Full Text] [Related]
17. Platelet-mediated thrombosis in stenosed canine coronary arteries: inhibition by nicergoline, a platelet-active alpha-adrenergic antagonist.
Bolli R; Ware JA; Brandon TA; Weilbaecher DG; Mace ML
J Am Coll Cardiol; 1984 Jun; 3(6):1417-26. PubMed ID: 6715702
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of acute platelet thrombosis formation in stenosed canine coronary arteries by specific serotonin 5HT2 receptor antagonist ritanserin.
Torr S; Noble MI; Folts JD
Cardiovasc Res; 1990 Jun; 24(6):465-70. PubMed ID: 2117499
[TBL] [Abstract][Full Text] [Related]
19. Thromboxane A2 and serotonin mediate coronary blood flow reductions in unsedated dogs.
Eidt JF; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT
Am J Physiol; 1989 Sep; 257(3 Pt 2):H873-82. PubMed ID: 2782444
[TBL] [Abstract][Full Text] [Related]
20. Localized administration of sodium nitroprusside enhances its protection against platelet aggregation in stenosed and injured coronary arteries.
Willerson JT; Igo SR; Yao SK; Ober JC; Macris MP; Ferguson JJ
Tex Heart Inst J; 1996; 23(1):1-8. PubMed ID: 8680268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
